Imunofan vs LL-37
Overview
Imunofan and LL-37 are both immune support peptides, but they differ in mechanism, dosing, and regulatory status.
This page compares Imunofan and LL-37 across their primary use, typical dosing, reported benefits and side effects, and U.S. regulatory status. For the full monograph on either compound — mechanism of action, clinical research, and references — follow the article links.
Side-by-side comparison
| Imunofan | LL-37 | |
|---|---|---|
| Category | Immune Support | Immune Support |
| Regulatory status (US) | Research use only | Not approved — Cat. 2 removed (Apr 2026) |
| Typical dosage | — | 2-5 mg |
| Frequency | — | twice weekly |
| Reported benefits | Immune enhancement, detoxification support, antioxidant effects | Antimicrobial activity, immune modulation, wound healing, anti-inflammatory |
| Reported side effects | Limited published safety data | Generally safe, minimal side effects |
Key differences
Primary use. Imunofan is categorised under Immune Support, while LL-37 falls under Immune Support. Because they target a similar goal, they are common alternatives to weigh against each other.
Regulatory status. Imunofan: not FDA-approved; treated as a research compound. LL-37: not FDA-approved; removed from FDA's Category 2 in April 2026, which is not permission to compound it.
Dosing. Typical dosing for Imunofan is not catalogued. LL-37 is typically dosed at 2-5 mg (twice weekly).
Can you stack them?
Some protocols combine peptides, but stacking Imunofan and LL-37 has not been validated for safety or efficacy in controlled trials. Combining compounds can change their effects and risks. Nothing here is medical advice — consult a qualified healthcare provider before starting or combining any protocol.
Frequently asked questions
- What is the difference between Imunofan and LL-37?
- Imunofan and LL-37 are both immune support peptides, but they differ in mechanism, dosing, and regulatory status. Imunofan is not FDA-approved; generally classified as a research compound, whereas LL-37 is not FDA-approved; removed from FDA's Category 2 in April 2026, which is not permission to compound it.
- What is Imunofan used for?
- Russian immune peptide.
- What is LL-37 used for?
- Antimicrobial defense peptide.
- Can you take Imunofan and LL-37 together?
- Some users combine peptides within a single protocol, but stacking Imunofan and LL-37 has not been established as safe or effective in controlled trials. Neither this comparison nor PeptideSciences101 is medical advice — consult a qualified healthcare provider before combining any compounds.
- Is Imunofan or LL-37 FDA-approved?
- Imunofan is not FDA-approved; generally classified as a research compound. LL-37 is not FDA-approved; removed from FDA's Category 2 in April 2026, which is not permission to compound it.